Efficacy News and Research

RSS

MRE reduces ionizing radiation exposure, detects Crohn's disease as reliably as CT

A new study from Rhode Island Hospital has found that MR enterography (MRE) without the use of an anti-peristaltic agent were as reliable as CT enterography (CTE) in determining the presence of Crohn's disease.

16 Jun 2011

Antibiotics overprescribed for in home-care patients

A study of Canadian home-care patients suggests doctors may be overprescribing antibiotics for patients receiving ongoing medical care at home.

16 Jun 2011

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Results of a Phase 2 study sponsored by Somnus Therapeutics, Inc., add further evidence supporting the efficacy and safety of a novel bedtime therapeutic that addresses a major underserved need of insomnia patients: maintaining sleep.

16 Jun 2011

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Alkermes, Inc. today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and buprenorphine. TRD, which is also known as refractory depression, refers to depressive episodes that are not adequately controlled by standard antidepressant therapy.

15 Jun 2011

Galectin strengthens cancer drug patent portfolio in Europe

Galectin Therapeutics Inc. today announced that the European Patent Office has granted the Company a new patent, No. 02731178.6, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer".

15 Jun 2011

FDA issues final rulemaking on testing and labeling of sunscreen products

"FDA's recognition today of the important role sunscreens play in protecting the public not only from sunburn but also from skin cancer and premature aging due to the sun is a very significant victory for public health. The role of UV rays in causing skin damage and the role of sunscreens in protecting against this sun damage are widely acknowledged within the medical and scientific communities, and we're very pleased the agency has taken this critical step.

15 Jun 2011

Leukothera effectively treats psoriasis in humanized mouse xenograft transplantation model

Psoriasis is a persistent, long-lasting chronic skin disease affecting 2-3 percent of the world's population or more than 125 million individuals. For some, it is just a nuisance. For others, it is disabling.

15 Jun 2011

Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer

A type of virus known as the human reovirus possesses a remarkable trait: It can replicate inside and kill cancer cells that feature a common mutation, while leaving the body's normal cells alone.

15 Jun 2011

Meda presents new positive results from Dymista Phase-III trial on AR at EAACI 2011

Meda presents new positive results from a Phase-III clinical trial of Dymista at the annual meeting of the European Academy of Allergy and Clinical Immunology (EAACI) in Istanbul, Turkey.

15 Jun 2011

Biomoda receives U.S. patent to expand the use of CyPath assay for treatment of cancer

Cancer diagnostics company Biomoda, Inc. received Notice of Allowance for a U.S. Patent issued today that expands on use of the CyPath assay to include patient response to cancer therapy during the treatment phase of the disease.

15 Jun 2011

PDR launches new online network to collect, distribute adverse drug events in the U.S.

PDR Network and its partners today announced the launch of a new online network to collect and distribute adverse drug events in the United States.

From Physicians' Desk Reference (PDR) 15 Jun 2011

Interventions can buffer caregivers from stresses faced in providing care to terminally ill patients

Interventions can buffer caregivers of terminally ill patients from the significant stresses they face in providing care to a loved one, a new evidence review finds.

15 Jun 2011

Sangart commences MP4OX Phase 2b study in acute traumatic injury

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 2b study designed to evaluate the efficacy and safety of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock.

15 Jun 2011

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced it successfully completed patient enrollment in its phase II Contrast-Induced Acute Kidney Injury study with its oral drug candidate CRMD001.

14 Jun 2011

TWi Biotech enrolls over 50% of patients for AC-201 Phase IIb trial against Type II Diabetes

TWi Biotechnology Inc. announced today that the company has enrolled over 50% of the total 240 patients for the Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes.

14 Jun 2011

GE Healthcare announces results of Optison heart ultrasound contrast agent presented at ASE

Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison- (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in improving suboptimal echocardiograms.

14 Jun 2011

Cinryze data on hereditary angioedema presented at EAACI 2011

ViroPharma Incorporated today announced that data relating to Cinryze from nine accepted abstracts were presented as poster presentations at the 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI), June 11 through 15, in Istanbul, Turkey.

14 Jun 2011

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor.

14 Jun 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced an exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

13 Jun 2011

Efficacy News and Research

MRE reduces ionizing radiation exposure, detects Crohn's disease as reliably as CT

Antibiotics overprescribed for in home-care patients

Positive results from SKP-1041 Phase 2 study in insomnia patients with MOTN awakenings

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Galectin strengthens cancer drug patent portfolio in Europe

FDA issues final rulemaking on testing and labeling of sunscreen products

Leukothera effectively treats psoriasis in humanized mouse xenograft transplantation model

Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer

Meda presents new positive results from Dymista Phase-III trial on AR at EAACI 2011

Biomoda receives U.S. patent to expand the use of CyPath assay for treatment of cancer

PDR launches new online network to collect, distribute adverse drug events in the U.S.

Interventions can buffer caregivers from stresses faced in providing care to terminally ill patients

Sangart commences MP4OX Phase 2b study in acute traumatic injury

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

TWi Biotech enrolls over 50% of patients for AC-201 Phase IIb trial against Type II Diabetes

GE Healthcare announces results of Optison heart ultrasound contrast agent presented at ASE

Cinryze data on hereditary angioedema presented at EAACI 2011

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News